Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on

blood culture
beta-lactam
lactam
bacteremia
meropenem
  • 23 views
  • 28 Oct, 2021
  • 2 locations
Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple

tubal ligation
Accepts healthy volunteers
electrocardiograms
hysterectomy
beta-lactamase inhibitor
  • 0 views
  • 05 May, 2022
  • 1 location
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems

-lactamase inhibitor, have been the drug of choice. However, its use is limited in low- and middle-income countries. Thus, therapy of these infections mostly relies on polymyxins and other old drugs.

  • 0 views
  • 29 Sep, 2021
  • 2 locations
Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia (CEFTOREA)

The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.

ceftolozane/tazobactam
pseudomonas infections
tazobactam
  • 3 views
  • 04 Mar, 2022
SYN-004 Safety and Tolerability in Allo-HCT Subjects

Study Objectives: To evaluate the safety and tolerability of oral SYN-004 in adult allogeneic HCT (allo-HCT) recipients who develop fever after conditioning therapy and are treated with IV β-lactam antibiotics meropenem (MER), piperacillin tazobactam (PIP/TAZO), or cefepime (FEP). To evaluate potential absorption of oral SYN-004 into the systemic circulation of …

  • 0 views
  • 30 Apr, 2022
  • 1 location